BAJAJ BROKING

Notification close image
No new Notification messages
card image
Seshaasai Technologies Ltd IPO
Apply for the Seshaasai Technologies Ltd IPO through UPI in Just minutes
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

Marksans Pharma UK Regulatory Approval Adds Clonidine Formulations

Synopsis:


Relonchem, a Marksans Pharma subsidiary, has obtained MHRA approval for clonidine 100 µg and clonidine hydrochloride 25 µg tablets for the UK market.


Source:
Marksans Pharma Press Release (NSE Exchange Fillings) | Published on Oct 15, 2025

Disclaimer: This content has been published for informational purposes only. Bajaj Broking is not affiliated with, nor does it endorse or assume any responsibility for, the source material. Readers are advised to consult the original publication for complete and accurate context.

Marksans Pharma News Today

As quoted in the press release of Marksans Pharma (NSE Exchange Filings), Relonchem Limited, a fully owned UK subsidiary of the company, has received Marketing Authorization from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for two formulations of clonidine. These are clonidine 100 microgram tablets and clonidine hydrochloride 25 microgram tablets.

Also read: Adani Green Operationalises 50 MW Solar Project At Khavda, Gujarat

MARKSANS PHARMA LIMITED

Trade

177.7-3.01 (-1.66 %)

Updated - 16 October 2025
182.15day high
DAY HIGH
177.61day low
DAY LOW
392455
VOLUME (BSE)

Key Takeaways

  • Relonchem receives MHRA approval for two clonidine formulations in the UK.

  • The development strengthens Marksans Pharma’s product range in regulated markets.

  • Clonidine is widely used to manage hypertension and certain related conditions.

  • The company continues to maintain multiple global regulatory approvals.

Also read: AstraZeneca to Launch Sodium Zirconium Cyclosilicate Suspension In November 2025

Product Approval Details

The MHRA approval permits Relonchem to manufacture, market, and sell products based on clonidine in Great Britain. This further extends the company's footprint in the cardiovascular therapy space.

Product Name

Strength

Regulatory Body

Market

Clonidine Tablets

100 microgram

MHRA (UK)

United Kingdom

Clonidine Hydrochloride Tablets

25 microgram

MHRA (UK)

United Kingdom

Both products use clonidine as the active ingredient, which is known for its therapeutic applications in blood pressure management and related medical treatments.

Company Overview

Based in Mumbai, India, Marksans Pharma is involved in research, production, and sale of the generic pharmaceutical formulations. The company operates in a number of global markets and has production facilities in India, the United States and the United Kingdom.

The company facilities are compliant with regulations set forth by the US Food and Drug Administration (USFDA), the UK Medicines and Healthcare products Regulatory Agency (MHRA), and the Therapeutic Goods Administration (TGA). The approvals demonstrate compliance with strict quality requirements that are the standard in governed environments of pharmaceuticals.

Regulatory Context

The approval of clonidine products by Relonchem is another in a growing series of approvals from the MHRA. For many years Marksans Pharma has has consistent compliance at its manufacturing and distribution sites to the standards of global regulations in pharmaceuticals. The recent approval adds to approvals for other products approved for metformin extended release and baclofen tablets.

Share Price Update

As of 15 Oct 2025, Marksans Pharma share price stood at ₹180.15 per share on the BSE at 15:30 PM IST. This figure reflects the market’s ongoing assessment of the company’s fundamentals, risks, and growth prospects.

Read More Blogs

Disclaimer :

The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.

The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.

Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

[ Read More ]

For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

11 lakh+ Users

icon-with-text

4.6 App Rating

icon-with-text

4 Languages

icon-with-text

₹6,800+ Cr MTF Book

icon-with-text